


DVT/PE Duration of Treatment

(Recommendations from the America College of Chest Physicians 2016 Update on Antithrombotic Therapy for VTE¹)



^aGrades of evidence shown in parenthesis
 1=Strong recommendation 2=Weak recommendation
 A=High quality evidence B=Moderate quality evidence C=Low quality evidence

^bExtended therapy = no scheduled stop date; the continued use of anticoagulation should be reassessed at periodic intervals (e.g. annually)



^cEnvironmental Risk factors for VTE²= surgery, trauma, immobilization, central venous catheters, pregnancy/post-partum, chemotherapy, recent travel ,hormone therapy (ex. Oral/transcutaneous/vaginal contraceptives, depot progestin injections, hormone replacement therapy)

^dRisk Factors for Bleeding while on Anticoagulant Therapy

Age> 65 y	Anemia
Previous bleeding	Antiplatelet therapy
Cancer	NSAID
Alcohol abuse	Frequent falls
Recent surgery***	Poor anticoagulant control
Metastatic cancer	Diabetes
Renal failure	Previous stroke
Liver failure	Comorbidity and reduced functional capacity
Thrombocytopenia	

***Important for parenteral anticoagulation (eg, first 10 days), but less important for long-term or extended anticoagulation

	Risk Category	Bleed Risk 0-3 months	Bleed Risk After 3 months
0 risk factors	Low	1.6%	0.8%/year
1 risk factor	Moderate	3.2%	1.6%/year
≥ 2 risk factors	High	12.8%	≥6.5%/year



^eRisk factors for extension of distal DVT that would favor anticoagulation over surveillance:
 D-dimer is positive
 Thrombosis is extensive (> 5 cm in length, involves multiple veins, >7 mm in max diameter)
 Thrombosis is close to the proximal veins
 No reversible provoking factor for DVT
 Active cancer
 History of VTE
 Inpatient status

Spontaneous superficial vein thrombosis
 Prophylactic parenteral anticoagulation for at least 45 days³

Adapted from:

1. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST guideline and Expert Panel Report. Chest 2016; 149 (2):315-352.
2. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 2016;41:32-67.
3. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2)(suppl):e419S-e496S.

Created by Tram Le, PharmD Candidate 2017 and Crystal Franco-Martinez, PharmD, BCPS, 6/2016
 Approved by Anticoagulation Safety Committee 8/2016
 P&T Approved 10/2016